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Background: Dehorning is a common practice involving calves on dairy operations in the United States. However,
less than 20% of producers report using analgesics or anesthetics during dehorning. Administration of a systemic
analgesic drug at the time of dehorning may be attractive to dairy producers since cornual nerve blocks require
10 – 15 min to take effect and only provide pain relief for a few hours. The primary objectives of this trial were to
(1) describe the compartmental pharmacokinetics of meloxicam in calves after IV administration at 0.5 mg/kg and
(2) to determine the effect of meloxicam (n = 6) or placebo (n = 6) treatment on serum cortisol response, plasma
substance P (SP) concentrations, heart rate (HR), activity and weight gain in calves after scoop dehorning and
thermocautery without local anesthesia.
Results: Plasma meloxicam concentrations were detectable for 50 h post-administration and fit a 2-compartment
model with a rapid distribution phase (mean T½α= 0.22 ± 0.087 h) and a slower elimination phase (mean
T½β= 21.86 ± 3.03 h). Dehorning caused a significant increase in serum cortisol concentrations and HR (P < 0.05). HR
was significantly lower in the meloxicam-treated calves compared with placebo-treated calves at 8 h (P = 0.039) and
10 h (P = 0.044) after dehorning. Mean plasma SP concentrations were lower in meloxicam treated calves
(71.36 ± 20.84 pg/mL) compared with control calves (114.70 ± 20.84 pg/mL) (P = 0.038). Furthermore, the change in
plasma SP from baseline was inversely proportional to corresponding plasma meloxicam concentrations (P = 0.008).
The effect of dehorning on lying behavior was less significant in meloxicam-treated calves (p = 0.40) compared to
the placebo-treated calves (P < 0.01). Calves receiving meloxicam prior to dehorning gained on average
1.05 ± 0.13 kg bodyweight/day over 10 days post-dehorning compared with 0.40 ± 0.25 kg bodyweight/day in the
placebo-treated calves (p = 0.042).
Conclusions: To our knowledge, this is the first published report examining the effects of meloxicam without local
anesthesia on SP, activity and performance of calves post-dehorning. These findings suggest that administration of
meloxicam alone immediately prior to dehorning does not mitigate signs of acute distress but may have long term
physiological, behavior and performance effects.
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Dehorning is one of the most common practices involv-
ing calves on dairy operations in the United States [1].
Although the American Veterinary Medical Association
recommends the use of practices which reduce pain
associated with dehorning, there are currently no drugs
approved for analgesia in cattle in the United States [2].
Meloxicam is a non-steroidal anti-inflammatory drug
(NSAID) of the oxicam class that is approved in the
European Union for adjunctive therapy in the treatment
of cattle for acute respiratory disease; diarrhea and acute
mastitis when administered at 0.5 mg/kg IV or SC [3].
Meloxicam has recently been approved in Canada for
improving appetite and weight gains at the onset of diar-
rhea (calves > 1 w of age) and relief of pain following de-
budding of horn buds in calves less than 3 months of
age. Heinrich et al. (2009) demonstrated that 0.5 mg/kg
meloxicam IM combined with a cornual nerve block
reduced serum cortisol response for 6 hours in 6-12 wk
old calves compared with calves receiving only local
anesthesia prior to cautery dehorning [4]. Furthermore,
calves receiving meloxicam had lower heart rates and re-
spiratory rates than placebo treated control calves over
24 hours post-dehorning. Stewart et al. (2009) found that
meloxicam administered IV at 0.5 mg/kg mitigated the
onset of pain responses associated with hot-iron dehorn-
ing in 33 ± 3 day-old calves compared with administra-
tion of a cornual nerve block alone as measured by heart
rate variability and eye temperature [5]. Heinrich et al.
(2010) reported that meloxicam treated calves were less
active than controls for 5 hours after dehorning and dis-
played less sensitivity to pressure algometry 4 h after
dehorning compared with administration of a cornual
nerve block alone [6]. Ingvast-Larsson et al. described
the pharmacokinetics of meloxicam in goats and
observed fewer signs of distress in treated kids compared
with controls after dehorning [7]. These findings indicate
that administration of meloxicam at 0.5 mg/kg IV or IM
decreases behavioral and physiological responses linked
to pain and distress associated with cautery dehorning.
In previous studies, a reduction in signs of distress fol-
lowing systemic meloxicam administration prior to
dehorning was achieved in combination with local
anesthesia provided with a cornual nerve block [4-6].
However, a survey of North-Central and North-Eastern
United States dairy producers found that only 12.4% of
dairy owners use local anesthetic nerve blocks and only
1.8% provide systemic analgesia at the time of dehorning
[8]. Similarly, only 18% of Wisconsin dairy producers re-
port using local anesthetics prior to dehorning [9]. These
data are consistent with the results of the recent Na-
tional Animal Health Monitoring System (NAHMS) sur-
vey that reported that only 13.8 percent of U.S
operations report using analgesics or anesthetics duringhot iron dehorning [1]. Administration of effective sys-
temic analgesia at the time of dehorning instead of local
anesthesia may be attractive to dairy producers since
cornual nerve blocks delay cattle processing because
these require 10 – 15 minutes to take effect [10].
The effects of meloxicam administration without local
anesthesia on post-surgical behavior and performance in
older calves (> 16 weeks of age) have not been described.
In addition, the compartmental pharmacokinetics of
meloxicam administered intravenously to calves sub-
jected to dehorning procedures has not been reported. If
meloxicam administration alone mitigates pain and dis-
tress and is associated with quantifiable performance
benefits when administered prior to dehorning, this
would provide producers and veterinarians with a prac-
tical and cost-effective way to reduce pain and distress
after dehorning. The primary objectives of this trial were
to (1) describe the compartmental pharmacokinetics of
meloxicam in calves after IV administration at 0.5 mg/kg
and (2) to determine the effect of meloxicam on cortisol
response, substance P (SP) concentrations, heart rate
(HR), activity and weight gain in calves after scoop
dehorning and thermocautery without local anesthesia.
Results
No calves were determined to require rescue analgesia
during the course of the study.
Meloxicam pharmacokinetics
The average observed and predicted plasma time-
concentration curve of meloxicam following IV adminis-
tration at 0.5 mg/kg bodyweight in calves is presented in
Figure 1. The data fit a 2-compartment model character-
ized by rapid distribution of meloxicam from the central
to the peripheral compartment followed by a slower de-
cline in mean plasma meloxicam concentrations governed
by metabolism and excretion processes. The mean phar-
macokinetic parameters calculated after fitting this model
to the data are summarized in Table 1.
Cortisol
Mean serum cortisol concentrations over time for the
meloxicam and placebo treated groups are presented in
Figure 2. There were no significant differences in cortisol
concentrations noted between treatment groups at any
time point. Mean cortisol concentrations were 57.62 ±
11.62 nmol/L in the control group and 42.10 ± 11.62
nmol/L in the meloxicam treated group (P= 0.35). Corti-
sol concentrations in both treatment groups were signifi-
cantly higher at 10, 15, 20 and 30 minutes after
dehorning compared the other time points (P< 0.01).
However, there was no evidence of a time by treatment
interaction (P=0.85). Mean non-compartmental analysis






















































Figure 1 Average predicted time-concentration curve compared to observed data (± standard deviation; n = 6 calves) after
administration of meloxicam at 0.5 mg/kg IV. Linear and semi-log scale (inset) plots.
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AUEC between treatment groups (P>0.05). There was
also no association between the log transformed percent
change in cortisol concentrations and the corresponding
plasma meloxicam concentrations at each timepoint
(P=0.45).Substance P (SP)
Mean (± SEM) SP concentrations were 114.70 ± 20.84
pg/mL in the control calves and 71.36 ± 20.84 pg/mL
in the meloxicam treated calves (P=0.038) (Figure 3).
There was no evidence of an effect of time (P=0.29)
or a time by treatment interaction (P=0.16) on log-
transformed plasma SP concentrations. The back
transformed estimate of the difference between aver-
age SP concentration in meloxicam and placebo-
treated calves was 0.50 (95% Confidence interval: 0.26
to 0.96). Therefore, the plasma SP concentration is
estimated to be 0.5 times less in the presence of
meloxicam treatment than in the absence of treatment
in calves after dehorning (95% Confidence interval:0.26 to 0.96 times). Furthermore, there was an inverse
relationship between log-transformed meloxicam con-
centrations and log-transformed SP percent change
from baseline (P=0.008) with the regression curve
described by the equation Log SP% Change =
3.4475533 - 0.9440988*Log Meloxicam (Figure 4).Activity and behavior
Data from one calf (calf number 7, meloxicam group)
was not available for analysis due to accelerometer mal-
function resulting in loss of data. The effect of dehorning
on lying behavior was modified by meloxicam adminis-
tration, as evidenced by the significant (p< 0.01) inter-
action between time relative to dehorning (pre vs. post)
and treatment group (meloxicam vs. control). Calves in
the control group spent a lower proportion (42.7%) of
time lying post-dehorning compared to pre-dehorning
(46.1%); however, there were no significant differences
(p=0.40) in the proportion of time the meloxicam calves
spent lying pre- or post-dehorning (43.1%, 43.0%, re-
spectively) (Figure 5).
Table 1 Mean plasma pharmacokinetic parameters for
meloxicam after IV administration at 0.5 mg/kg
bodyweight determined using a two- compartment
model
Parameter Units Mean Standard error
Vc mL/kg 94.88 9.04
V2 mL/kg 99.07 7.85
Vss mL/kg 193.94 10.34
CL mL/h/kg 6.64 0.76
CLD2 mL/h/kg 225.18 47.43
T½α hr 0.22 0.087
T½β hr 21.86 3.03
AUC hr*ug/mL 81.02 10.58
MRT hr 31.24 4.37
K10 1/h 0.075 0.012
K12 1/h 2.70 0.78
K21 1/h 2.20 0.39
Vc, - volume of the central compartment; V2 - volume of the peripheral
compartment; Vss- apparent volume of distribution at steady-state; CL - total
body clearance; CLD2: - distributional clearance from the central compartment
to the peripheral compartment; T½α and T½β half-lives for the distribution
phases; AUC- area under the time-concentration curve; MRT- mean residence
time of the drug in the body; k12 and k21 - μ-rate constants for the drug’s
movement between the central and peripheral compartments; and
k10 - elimination rate constant.
Table 2 Mean peak serum cortisol concentrations (Cmax),
time to peak concentration (Tmax) and area under the
time-effect curve (AUEC) for cortisol determined using
non-compartmental analysis
Cortisol parameters Control Meloxicam P value
Tmax (min) 15.83 ± 4.92 19.17 ± 9.17 0.68
Cmax (nmol/L) 159.17 ± 11.032 165.00 ± 14.84 0.76
AUEC minute●nmol/L 133,584 ± 18,039 122,961 ± 20,441 0.70
Cmax Peak cortisol concentrations.
Tmax time to peak cortisol concentration.
AUEC area under the time-effect curve for cortisol determined using non-
compartmental analysis.
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After periods of missing data were removed there were
156,398 data points available for analysis. The compari-
















Figure 2 Mean (± SEM) serum cortisol concentrations (nmol/L) in calv
30 s) prior to dehorning. There were no significant differences between tdehorning in meloxicam and placebo treated calves is
presented in Figure 6. The mean HR was not signifi-
cantly different between calves assigned to the control
group (91.85 ± 3.82 beats/minute) and the meloxicam
treated group (90.27 ± 4.19 beats/minute) prior to
dehorning (p= 0.79). However, after dehorning, the mean
HR in calves in the placebo treated control group in-
creasing to 94.83 ± 3.82 beats/minute (p < 0.0001) and
in the meloxicam treated calves increased to 97.72 ±
4.19 beats/minute (p< 0.0001). There was however no
difference in overall HR between the two treatment
groups during the entire post-dehorning period (p=0.62).
In order to address issues with model stability and con-
vergence when examining hourly changes in HR after
treatment, data were truncated to 20,000 data points col-
lected at 15 sec intervals over 12 h after dehorning
(Figure 7). This allowed evaluation of the effect of60 360 1320 1800 2700 3120
t-dehorning (minutes)
Meloxicam
es receiving 0.5 mg/kg meloxicam or placebo IV immediately (<
























Figure 3 Mean (± SEM) plasma Substance P concentrations (nmol/L) in calves receiving 0.5 mg/kg meloxicam or placebo IV
immediately (< 30 s) prior to dehorning. Columns not connected by a symbol of the same shape and color are significantly different (P < 0.05).
Figure 4 Linear regression fit (solid line) and 95% confidence interval (dotted line) of log transformed plasma substance P (SP) percent
change from baseline concentrations compared with log meloxicam concentrations. There was a negative correlation between log
meloxicam concentrations and% change in SP (P = 0.008) described by the equation Log SP% Change= 3.4475533 - 0.9440988*Log Meloxicam.

































Figure 5 Model estimated proportion of time calves spent lying by treatment group and time relative to dehorning (pre = 48 h,
post = 168 h). Model included random effects for calf identification and trial replicate. Columns not connected by a symbol of the same shape
and color are significantly different (P < 0.05).
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mediately following dehorning. There wasevidence of an
effect of time (P <0.0001) and a time by treatment inter-
action (P <0.0001) on HR over this period. Mean HR was
significantly elevated over the first 6 hours after dehorning





















Figure 6 Mean (± SEM) heart rate (beats/min) in calves over 48 h befo
immediately (< 30 s) prior to dehorning. Columns not connected by a swith the heart rate from 7 to 12 h after dehorning (Range:
86.79 to 97.30 beats/minute). The difference in mean HR
in calves treated with meloxicam compared to placebo-
treated calves approached significance at 7h after dehorning
(P=0.0639) and was significantly lower at 8 h (P=0.034) and
10 h (P=0.045) after dehorning.macixoleM
ent Groups
g Post-dehorning
re and after receiving 0.5 mg/kg meloxicam or placebo IV
ymbol of the same shape and color are significantly different (P < 0.05).
Figure 7 Mean (± SEM) heart rate (beats/min) in calves collected every 15 s over 12 h after receiving 0.5 mg/kg meloxicam (▲) or
placebo (□) IV immediately (< 30 s) prior to dehorning. Data points not connected by a symbol of the same shape are significantly different
(Pthinsp;< 0.05).
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During the 19 days preceding the current study, there
was no significant difference (P= 0.41) in mean ADG in
body weight (± SD) for calves in the meloxicam groupFigure 8 Mean Average Daily Gain (ADG) (Kg) (+/− SEM) 10 days post
mg/kg IV prior to dehorning. Columns not connected by a symbol of th(0.86 ± 0.19 kg/calf/day) and the control group (1.02 ±
0.41 kg/calf/day). The mean ADG in calves in the pla-
cebo or meloxicam treated groups 10 days after dehorn-
ing is presented in Figure 8. Calves receiving meloxicam-dehorning after placebo or meloxicam administration at 0.5
e same shape and color are significantly different (P < 0.05).
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day over 10 days post dehorning. This was significantly
greater than the mean average daily gain in bodyweight
of 0.40 ± 0.25 kg/day in the control group over the same
period (p=0.0418).
Discussion
The primary objectives of this trial were to describe the
compartmental pharmacokinetics of meloxicam in calves
after IV administration at 0.5 mg/kg and to determine the
analgesic effect of meloxicam after scoop dehorning and
thermocautery without local anesthesia. Surgery-induced
pain and central sensitization consist of two phases: an im-
mediate incisional phase and a prolonged inflammatory
phase that arises primarily due to tissue damage [11].
Demonstrating the adequacy of preemptive analgesia has
two basic requirements [11]. The first is to demonstrate
the direct pharmacological effect of the analgesic. This was
accomplished in the present study by comparing differ-
ences in acute biomarkers of pain and distress including
substance P, cortisol response and heart rate between trea-
ted and control subjects. The second requirement is to
demonstrate the extension of the antinociceptive effect
into the postoperative period when pain due to inflamma-
tion becomes the dominant process [11]. In practical
terms, two approaches have been used to demonstrate the
efficacy of preemptive analgesic regimens. The first is to
demonstrate a reduction in pain intensity beyond the pres-
ence of the drug in the biophase in studies involving trea-
ted and untreated control subjects. The second approach
is to demonstrate that a treatment applied before surgery
is more effective than the treatment applied at the end of
surgery [11]. In the present study, we used pharmacoki-
netic analysis to determine the presence of meloxicam in
the biophase and cortisol, SP and heart rate analysis to de-
termine the direct pharmacological effect of meloxicam in
treated and untreated calves. Continuous, telemetric as-
sessment of posture and activity over 96 hours after
dehorning and weight gain over 10 days was used to deter-
mine if meloxicam effects extended into the post-operative
period.
In the present study, plasma meloxicam concentrations
were still quantifiable in the last sample, at 52 hours
post-injection, and showed a bi-exponential decay fol-
lowing administration. The initial steep decline in plasma
concentrations was likely due to the rapid distribution of
the drug from the central to the peripheral compart-
ment. This was followed by a slower decline in plasma
concentrations associated with drug metabolism and ex-
cretion. Although exceptions due to species and drug
compound exist, NSAIDs in general tend to be highly
protein-bound in the plasma which limits distribution
into the tissue, leading to low volume of the central com-
partment and low volume of distribution [12] as wasseen in the current study. The extended half-life of
meloxicam in cattle is likely due to a low total body
clearance representing mostly hepatic clearance since
high levels of protein binding tend to limit glomerular
filtration of drug compounds.
The clinical implication of the slow elimination of
meloxicam from the body is that infrequent drug adminis-
tration (once every few days) may be sufficient to mitigate
pain effects due to post-surgical inflammation in calves. It
was recently reported that generic meloxicam tablets have
100% bioavailability following oral administration in ru-
minant calves suggesting that this may provide a practical
and cost effective alternative to IV administration in those
animals [13]. The pharmacokinetic profile of meloxicam
described in the current report along with the associated
effects on behavior and performance suggest that adminis-
tration immediately prior to dehorning may have effects
for several days post-dehorning. Given that the plasma
half-life of meloxicam is longer than previously reported
for ketoprofen (0.42 h) [14], salicylate (0.5 h) [15] and flu-
nixin (4- 8 h) [16], these results suggest that meloxicam
may have an extended duration of activity compared with
other NSAIDs currently available in the U.S. However, fur-
ther research is needed to determine if the effect of these
analgesics is directly related to plasma drug concentra-
tions, and if so, to determine the effective range. Although
the literature is deficient in studies with cattle, the effective
plasma concentration (EC50) of meloxicam is estimated to
be 0.73 μg/mL in the horse [17] and 0.36 μg/mL in the
dog [18]. If cattle respond to meloxicam as horses and
dogs, the effective plasma drug concentration would be
maintained for several days following IV administration of
meloxicam at 0.5mg/kg.
Cortisol, substance P and heart rate analysis was used
as an indicator of the direct pharmacological effect of
meloxicam on pain and distress associated with dehorn-
ing in treated and untreated calves. It has been reported
that plasma cortisol concentrations reach a peak within
30 minutes after dehorning after which levels decrease to
a plateau concentration that persists for 5 – 6 hours
[19,20]. The results presented here are consistent with
previous reports that demonstrate a significant increase
in plasma cortisol concentration after dehorning [4,5,21].
However, in contrast with the findings of Heinrich and
others [4], the present study failed to demonstrate that
calves receiving meloxicam prior to dehorning had lower
cortisol concentrations compared with untreated con-
trols. This may be due to differences in the blood collec-
tion schedule that was designed to minimize the effect of
animal handling on behavioral assessment. Furthermore,
the present study enrolled older calves (<3mo vs. >4 mo)
and necessarily employed a different method of dehorn-
ing (cautery disbudding vs. amputation). Since the horn
bud attaches to the skull of calves at approximately 2
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communicating with the frontal sinus, removal of the
horn tissue is generally considered more invasive and
stressful in older animals resulting in higher cortisol con-
centrations [22].
The most likely explanation for the differences in cortisol
response is that previous reports frequently combined
NSAID administration with local anesthesia. Local anes-
thetics mitigate acute incisional pain by blocking voltage-
gated sodium channels in the nerves preventing the gener-
ation and propagation of nerve impulses or action poten-
tials [10]. In the bovine, this effect lasts approximately 2 – 3
h after dehorning with the provision of a lidocaine block of
the cornual nerve [10,20]. Lidocaine local anesthesia com-
bined with systemic ketoprofen administration prior to
dehorning significantly attenuates the plasma cortisol re-
sponse compared with the effect of the agents administered
separately [19,20,23]. The reason why we chose not to ad-
minister local anesthesia in the present study was because
surveys suggest that less that 20% of U.S. dairy producers
currently use local anesthetics prior to dehorning and our
goal was to look at the effect of an NSAID without local
anesthesia [1,8,9]. The absence of an effect of meloxicam on
acute cortisol response suggests that provision of systemic
analgesia alone without local anesthesia is inadequate in
providing adequate preemptive analgesia using the defin-
ition provided by Kissin, 2000 [11].
Substance P is an 11-amino acid prototypic neuropep-
tide that regulates the excitability of dorsal horn nocicep-
tive neurons and is expressed in areas of the neuroaxis
involved in the integration of pain, stress, and anxiety [24].
It has been reported that plasma SP concentrations are
significantly higher in beef calves after castration com-
pared with uncastrated controls [25]. In the present study,
mean plasma substance P concentration was estimated to
be reduced by 50% (95% Confidence interval: 26 to 96%)
in calves that received meloxicam prior to dehorning com-
pared with placebo-treated controls. Furthermore, we
observed that increases in plasma substance P concentra-
tions from baseline corresponded with lower log plasma
meloxicam concentrations. These findings support the hy-
pothesis that meloxicam treatment mitigates SP release
and therefore potentially reduced pain perception in calves
after dehorning without local anesthesia. To our know-
ledge this is the first study that has demonstrated a rela-
tionship between substance P concentrations and
analgesic drug concentrations after dehorning. This sug-
gests that SP measurement may have potential to be used
as a biomarker for determining analgesic drug efficacy in
calves subjected to painful procedures. Furthermore, the
absence of an effect of meloxicam treatment on serum
cortisol concentrations suggests that simultaneous deter-
mination of plasma SP and cortisol concentrations during
painful procedures may assist in differentiating betweenacute stress associated with handling and distress asso-
ciated with nociception as previously described [25].
Normal HR in unstressed cattle range from 70 to 90
bpm [26] but mean HR has been shown to increase by
30 to 40 bpm over baseline levels by stressful events such
as branding, electric shock and handling prior to dehorn-
ing and castration [21,27,28]. Schwartzkopf-Genswein
and others reported that HR in dehorned calves was sig-
nificantly higher that control animals for 120 minutes
after the procedure [21]. Similarly, Grondahl-Nielsen
et al. (1999) observed that HR was elevated for 3.5 h in
dehorned calves receiving no anesthetic or analgesic
compared with calves that were only sham dehorned
[29]. Likewise, Stewart et al, 2009 observed that HR was
raised above baseline for 3 h after dehorning without
local anesthesia [5]. Heinrich et al (2009) observed a
greater increase in HR, measured by thoracic ausculta-
tion at 7 time points over 24 h, in placebo-treated calves
compared with calves that received 0.5 mg/kg meloxicam
IM combined with corneal nerve block at 10 minutes
prior to dehorning [4]. In the present study, baseline HR
was higher than previously reported and were main-
tained above 100 bpm for 6 hours after dehorning in
both treatment groups. This difference could be attribu-
ted to the use of older calves (16 – 20 wks vs. < 6 wks)
than what had been used in previous experiments. In
our study we observed a significant decrease in mean
HR in meloxicam-treated calves at 8 and 10 hours after
dehorning. These results support the conclusions of
Heinrich and others (2009) [4] that meloxicam reduces
the stress response after dehorning as reflected by in
changes in heart rate even in the absence of local
anesthetic administration at the time of dehorning.
Comparison between calf behavior before and after
dehorning and assessment of weight gain over 10 days
post-dehorning was used to determine if meloxicam
effects extended into the post-operative period. It was re-
cently reported that calves that received oral meloxicam
at 1 mg/kg spent more time lying down over 4 days
compared with placebo-treated control calves [30]. The
amount of time cattle exhibit specific behaviors is com-
monly used to indicate comfort and/or clinical illness
[31-34]. An increase or decrease in lying behavior, how-
ever, does not expressly indicate pain or comfort and
must be interpreted within the context of what is normal
for a particular animal. Cattle in pain due to lameness
have been observed to lie more [35] whereas cattle in
pain due to dehorning and castration have been observed
to lie less than nonpainful controls [6,30,36,37]. Further-
more, lying behavior among individual cattle within a
herd has been observed to vary more than lying behavior
between herds [34]. Therefore, within-animal compari-
sons, such as implicitly occurs with an analysis such as
in the current study comparing an individual’s control
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cedure) behavior, are likely to be more sensitive than
between-animal comparisons in detecting changes due
to a particular treatment. Since meloxicam-treated calves
were intermingled equally with placebo-treated calves,
the difference noted between groups in the pre-
procedure period is likely due to individual variation in
the normal amount of time spent lying.
It has been previously reported that calves that received
meloxicam at 0.5 mg/kg IM combined with corneal nerve
blocks were less active than controls during the first 5 h
following dehorning compared with placebo-treated con-
trols [6]. In the present study, calves receiving meloxicam
without local anesthesia demonstrated no significant dif-
ference in lying activity before and after dehorning. In con-
trast, control calves spent less time lying after dehorning,
and although the percentage difference was numerically
small (3.4%), this difference was significant due to the
associated small standard error. This is similar to the
results reported by Theurer and others (2012) that
observed differences in lying behavior for 5 days after
dehorning in calves that received oral meloxicam at 1 mg/
kg [30]. When considering a 3.4% difference over a 24
hour period, control calves stood an average of 49 minutes
more per day after dehorning than before. In meloxicam
calves, the absence of an effect of dehorning on lying be-
havior may have been due to the analgesic activity of the
drug. These results suggest that meloxicam mitigates be-
havioral effects of dehorning even in the absence of local
anesthetic administration.
Studies reporting a difference in weight gain between
analgesic-treated and unmedicated calves after dehorning
are deficient in the published literature. Previously, Faul-
kner and Weary (2000) demonstrated that calves receiv-
ing ketoprofen prior to dehorning tended to gain more
weight during the 24 h after dehorning than untreated
calves [38]. However, during the subsequent 24 hour
period, weight gains were similar between the two
groups. Administration of the NSAID, sodium salicylate
in drinking water for 2 d after dehorning and castration
was found to increase ADG over 13 d [39]. Over the 10
day duration of the present study, calves receiving
meloxicam gained significantly more weight than those
in the control group, with a mean difference of 0.65 ±
0.28 kg/day (p=0.0418). This finding supports the hy-
pothesis that extended exposure to a non-steroidal anti-
inflammatory drug (NSAID) may maintain growth and
performance after castration.
Although studies reporting a performance benefit after
NSAID administration 2- 3 weeks following processing
and castration are deficient in the published literature,
meloxicam administration has been associated with
improved average daily gain in calves suffering from clin-
ical bovine respiratory disease [40]. Therefore, in orderto definitively attribute the observed difference in ADG
to the effect of meloxicam on pain and inflammation
associated only with dehorning, future studies should
also include additional meloxicam treated and untreated
control calves that are processed but not dehorned.
The biological explanation for the improved ADG
observed in this study was not investigated. Meloxicam
treated and untreated control calves were co-mingled in
pens for the duration of the study precluding assessment
of individual animal feed intake or feed efficiency. Fur-
thermore, even though the accelerometer analysis
revealed significant differences in the pre and post-
dehorning behavior of control calves, this technology is
currently not sufficiently sensitive to characterize subtle
differences in feeding and walking behavior that could
contribute to performance differences. However, Theurer
and others [30] recently reported that calves that
received oral meloxicam prior to dehorning spent more
time at the grain bunk and less time at the hay feeder
compared to the control group which could explain the
difference in weight gain observed in the present study.
Another possible contributory factor to the performance
difference is that increased activity of nociceptors
increases sympathetic tone and adrenal secretory activity
which may inhibit gastric centers causing decreased
rumen motility [41]. Mellor and others (2002) reported a
significant increase in plasma adrenaline and noradren-
aline concentration for 5 and 50 minutes respectively
after scoop dehorning in 10 week old calves [42]. Adren-
ergic influences on reticuloruminal motility comprise de-
pression of the gastric centers resulting in inhibition of
intrinsic and extrinsic rumen motility [43]. The duration
of these effects and how these relate to plasma catechol-
amine concentrations has not been reported. Future
studies examining individual or pen level feed intake and
feed efficiency and the association with rumen motility
after dehorning may help explain the difference in ADG
observed in this report.
Conclusion
The results of this trial support the conclusions of previous
reports that observed a significant effect of meloxicam on
behavior and heart rate changes after dehorning with local
anesthesia [4,6,30]. However, we failed to detect an effect of
meloxicam administered without local anesthesia on serum
cortisol concentrations. This suggests that systemic admin-
istration of an NSAID does not adequately mitigate acute
signs of distress associated with dehorning. This study con-
tributes to the body of literature by demonstrating for the
first time that meloxicam administration significantly
reduces plasma substance P concentrations and that an in-
verse relationship exists between meloxicam concentrations
and changes in circulating SP concentration after dehorn-
ing. To our knowledge, this is also the first published report




NEm Megcal/CWT. 83.10 95.23
NEg Megcal/CWT. 54.62 62.59
TDN% 76.46 87.62
Fat 4.61 5.29










Cobalt ppm 0.06 0.07
Copper ppm 5.94 6.8
Iron ppm 50.64 58.0
Manganese ppm 20.75 23.8
Selenium ppm 0.14 0.17
Zinc ppm 309.55 354.7
NEm Megcal/CWT –Megcal of Net Energy for Maintenance (NEm) available per
100 lb (CWT) of feed; NEm Megcal/CWT – Megcal of Net Energy for
Maintenance (NEm) available per 100 lb of feed; TDN - Total Digestible
Nutrients; ADF - Acid Detergent Fiber; NDF – Neutral Detergent Fiber; eNDF –
Effective NDF; ppm – parts per million.
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tion on plasma substance P concentrations and weight gain
after dehorning. These results have implications for devel-
oping pain mitigation strategies involving NSAIDs in calves
at dehorning with respect to addressing both animal per-
formance and welfare concerns.
Methods
All experimental procedures in this study were approved
by the Kansas State University (KS) Institutional Animal
Care and Use Committee (IACUC) under the supervi-
sion of the University Veterinarian (Protocol #2694).
Since a placebo-treated, dehorned control group was en-
rolled in the study, calves were assessed hourly for be-
havioral signs of excessive pain over a period of 10 hours
after surgery. This was followed by twice daily monitor-
ing for 7 days. Calves demonstrating postural changes,
prolonged recumbency, anorexia and depression were
scheduled to receive rescue analgesia with flunixin
meglumine at 2.2 mg/kg IV, BID.
Animals
Twelve Holstein calves approximately 16-20 wks of age
and weighing between 140-205 Kg were acquired from a
commercial dairy located in South-West Kansas. Upon
arrival, the calves were given an eight-way clostridial vac-
cine (Covexin 8, Schering Plough), a single SQ injection
of tulathromycin (Draxxin, Pfizer) at 2.5 mg/kg body-
weight, and doramectin (Dectomax Pour-on, Pfizer)
administered topically at 500 μg/kg bodyweight. Ampro-
lium (Corid, Merial) was added to the drinking water to
provide 10 mg/kg PO for 5 days. Calves were maintained
in study housing facilities for 19 days prior to study
commencement.
Randomization and group assignment
Calves were blocked in pairs according to their weights
determined approximately 14 days prior to study com-
mencement. Calves were ranked by ascending weight in
kilograms and assigned a computer-generated random
number (Microsoft Excel 2007, Microsoft Corporation).
In each pair, the calf with the highest random number
was assigned to the meloxicam-treated group, while the
calf with the lowest random number was designated as a
placebo-treated control (n=6 calves/group).
Housing and husbandry
Calves were housed in groups of 6 animals (n=3
steers from each treatment group in each pen) in a
dry lot confinement facility at KSU Animal Resource
Facility for the duration of the study. Housing con-
sisted of an outdoor concrete pad (9.75m x 18.29m)
with a partial roof on straw bedding. During the
adaptation period, each calf was tied with a ropehalter to the pole fence within their pen for at least
10 minutes/day. Calves had free access to water and
brome hay for the entire housing period. A balanced
feedlot receiving ration composed of cracked corn,
wheat middlings, oats, soymeal and a protein/vitamin/
mineral supplement (Table 3) was fed at 3.6 kg/head/
day.
Catheterization and acclimatization
Approximately 48 hours prior to study commencement,
calves were restrained for jugular catheter placement
under local anesthesia. All study animals were fit with
two catheters, one catheter was designated for drug or
placebo administration and the other for blood sample
collection. Catheter patency was maintained using hep-
arin saline flush containing 3 USP units heparin sodium/
ml saline (Heparin Sodium Injection, Baxter Healthcare).
Catheters were removed immediately following drug ad-
ministration or final blood collection.
Following catheter placement, calves were restrained
twice daily using a rope halter to simulate study
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through the chute handling facilities once daily and
manipulated in the same manner as the proposed study
procedures. Cattle were also fitted with commercially
manufactured 3-dimensional accelerometers (GP1
SENSR, Reference LLC) at described in previous studies
[44]. The accelerometers were left on the calves until
study completion, approximately 7 days after placement.Treatment administration
Calves were subjected to either meloxicam or placebo
treatment as outlined below (n=6 steers/treatment). Doses
were calculated based on individual animal bodyweight
determined 14 hours prior to study commencement. The
IV dose was rounded to the nearest 0.5 ml and adminis-
tered using a 20 mL syringe. Meloxicam or the placebo
was administered immediately (<30 seconds) prior to com-
mencement of the dehorning procedure.
1) Intravenous (IV) injection of 0.5 mg/kg of meloxicam
(Metacam 5 mg/ml solution for injection (NADA
141-219), Boehringer Ingelheim Vetmedica, Inc; Lot
# 118ZN12) was administered as a single bolus in the
jugular vein using a designated catheter. The catheter
was flushed with 5 mL of heparin-saline and
removed immediately after administration.
2) Intravenous sodium chloride injection (0.9% Sodium
Chloride Injection USP, Baxter Healthcare Corp) was
administered at a volume based on a presumed dose
of 0.5 mg/kg meloxicam injection.
Observers and analytical chemists in the study were
masked to treatment group allocation.Dehorning
Prior to dehorning, all calves were restrained in a chute
with a head gate and a rope halter. The horn was removed
using a Barnes dehorning instrument (Stone Manufactur-
ing & Supply Company). Briefly, the opposing blades of
the instrument were aligned with the base of the horns at
the skin-horn junction. The handles of the instrument
were then closed slowly to ensure proper placement of the
instrument. Once optimal positioning was achieved, the
handles were spread quickly apart to engage the blades
and cut off the horn. Hemostasis was achieved through
thermocautery using a pre-heated electric dehorning iron
(Stone Manufacturing & Supply Company). All dehorning
procedures were performed by a single experienced veter-
inarian (BR). After dehorning, calves remained standing
but unrestrained in the chute for 20 minutes to facilitate
intensive blood sampling. Subsequent samples were col-
lected in housing pens with calves periodically restrained
using a rope halter.Blood sample collection
Eighteen milliliters of whole blood for cortisol, substance
P (SP) and meloxicam determination was collected into
syringes using the pre-placed jugular catheter immedi-
ately prior to drug or placebo administration, and at 5,
10, 15, 20, 30, 60 minutes and again at 6, 22, 30, 45 and
52 hours thereafter. Blood was immediately transferred
to 6 ml serum and lithium heparin vacutainer tubes (BD
Diagnostics) for cortisol and drug determination respect-
ively. Blood for SP determination was collected in 6 ml
EDTA tubes containing the serine protease inhibitor,
aprotonin at 500 KIU/mL of blood. The vacutainer tubes
were stored on ice for no more than 60 minutes pending
sample processing. Thereafter, blood samples were cen-
trifuged at 1,600 g for 15 minutes at 4°C. Serum and
plasma were pipetted from their respective tubes and
placed in cryovials for storage at -80°C prior to sample
analysis. All samples were analyzed within 60 days of
sample collection.
Cortisol determination
Serum cortisol concentrations were determined using a
solid-phase competitive chemiluminescent enzyme im-
munoassay and an automated analyzer system (Immulite
1000 Cortisol, Siemens Medical Solutions Diagnostics) as
previously described using an assay validated in bovine
plasma [15,45]. A sample volume of 100 μL was used in
each assay well. The reported calibration range for the
assay is 28 to 1,380 nmol/L with an analytical sensitivity
of 5.5 nmol/L.
Substance P determination
Plasma substance P concentrations were determined in
duplicate using a validated method as previously
described [25]. Briefly, Substance P was extracted from
plasma by acidifying with acetic acid and fractionating
with reverse-phase solid-phase extraction columns. The
peptide was eluted from the column using an organic-
aqueous solvent mixture and concentrated by drying
under nitrogen. The dried extract was reconstituted and
analyzed according to the manufacturer’s instructions in
the Substance P ELISA kit (Assay designs, Ann Arbor,
MI). The coefficient of variation between triplicate bo-
vine samples at each fortified SP concentration was <
30%. The linear regression line fit between the three
points at each of three control concentrations had a cor-
relation coefficient of 0.99.
Accelerometers
Activity data was collected for 48 and 168 hours pre-
and post-dehorning, respectively. Accelerometers
sampled at 100Hz and summarized values for the
selected variables every 5 seconds. Five variables were
recorded by the accelerometers for each 5-second
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(X, Y, and Z), the combined average magnitude for all
three axes, and the maximum combined vector magni-
tude. At trial completion, data were imported into com-
mercial data mining software (Insightful Miner,
Insightful Corporation), and a previously validated deci-
sion tree [30,36,44] was used to classify the behavior as
lying, standing, or walking for each 5 second interval.Heart rate determination
Heart rate data were recorded for 48 hours before and
after dehorning for each calf. Heart rate was recorded
and analyzed using a commercially available heart rate
monitor and software (RS800 and Polar Pro Trainer
Equine Edition, Polar Electro, Inc, Lake Success, NY) as
previously described [45]. The heart rate monitor con-
sisted of a transmitter placed over the heart in the left
foreflank attached to a girth strap placed around the
heart girth of the calves, and a wrist unit attached to the
elastic strap which received and recorded the signal from
the transmitter. Appropriate conductance for the electro-
des on the strap, one positioned on the sternum and one
over the right scapula, was facilitated by use of ultra-
sound gel (Medline Industries Inc. Mundeline, Il). The
transmitter measured the electric signal (ECG) of the
heart every 15 seconds. Prior to study commencement,
the heart rate wrist unit time was synchronized with the
stopwatches used for all other sample collection. The
corresponding heart rate within 15 seconds of each time
point was used for analysis.Average daily weight gain (ADG)
Calves were individually weighed on arrival, approxi-
mately 14 hours prior to dehorning and 10 days post-
dehorning using a commercial livestock scale (For-Most
Livestock Equipment). Food and water were not withheld
prior to weighing. Average daily gain (ADG) was calcu-
lated by subtracting the arrival from the pre-dehorning
weight and the pre-dehorning weight from the post-
dehorning weight and dividing this by the number of
days that passed between weigh dates.Plasma meloxicam determination
Plasma concentrations of meloxicam (m/z 352.09!114.90)
were determined with high-pressure liquid chromatography
(Shimadzu Prominence, Shimadzu Scientific Instruments)
and mass spectrometry (API 2000, Applied Biosystems) as
previously described [13,46]. With a limit of quantification
of 0.025 μg/mL, the standard curve was linear from 0.025
μg/mL to 10 μg/mL and was accepted if the correlation co-
efficient exceeded 0.99 and predicted values were within
15% of the actual values. The accuracy of the assay was
103 ± 7% of the actual value and the coefficient ofvariation was 7% determined on replicates of 5 each at
0.025, 0.5, and 5 μg/mL.
Pharmacokinetic analysis
Compartmental pharmacokinetic analysis of the meloxi-
cam time concentration data was performed using a com-
mercially available software program (WinNonlin,
Pharsight Corporation) as previously described [15,47].
Model selection was conducted using visual inspection of
predicted versus observed data plots and two measures of
goodness of fit (Aikaike Information Criterion and
Schwarz Bayesian Criterion).
Data analysis and statistics
Hypothesis tests were conducted using JMP 5.1.2 analyt-
ical software (SAS Institute, INC) unless otherwise speci-
fied [48]. For statistical analysis, the calf was considered
the experimental unit. The mean ± standard error of the
means (SEM) and the mean difference where appropriate
were calculated for each outcome variable at each time
point. Statistical significance was designated a priori at
p<0.05. Model fit was assessed by evaluating the form of
marginal studentized residuals versus fitted values plot.
The model was determined appropriate if the mean of
the residuals versus fitted values plot was centered on
zero.
For repeated measures data (heart rate, substance P
and cortisol concentrations at each time point), a ran-
dom effects-mixed model was constructed with treat-
ment, time and the interaction between time and
treatment designated as fixed effects. In this model, ani-
mal nested in treatment was designated as a random ef-
fect to account for the between subject effects. Where
significant interactions were detected, comparisons be-
tween different combinations were conducted using two-
sided Student t-tests. The experiment wise significance
level was protected by employing the Tukey method in
examining comparisons. Substance P data were not nor-
mally distributed and therefore these were log trans-
formed prior to statistical analysis. For heart rate data,
the statistical model failed to converge due to the large
number of data points relative to the number of animals
on trial and periods of missing data especially after 12 h
post-dehorning. Therefore, an initial analysis was con-
ducted on the cumulative data collected in the periods
before and after dehorning followed by a detailed ana-
lysis of the hourly data over 12 h post-dehorning.
Accelerometer data were imported into a commercial
data mining software (Insightful Miner, Insightful Cor-
poration, Seattle, WA), and a previously validated deci-
sion tree [36,44] was used to classify the behavior as
lying, standing, or walking for each 5 second interval.
Following classification, data were aggregated on an
hourly basis by the summing of the counts of 5-second
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ods of human intervention (feeding, sample collection,
animal processing, and treatment administration) were
removed equally from calves in both treatment groups.
The remaining hourly behavioral data from both repli-
cates of the trial were imported into a statistical program
(SAS 9.1, SAS Institute, Cary, NC) for analysis. The pro-
portion of time calves spent in each activity was modeled
using logistic regression (PROC GLIMMIX) to evaluate
potential associations between lying behavior and time
relative to dehorning (pre- or post-), treatment (Meloxi-
cam or control), and the interaction between these vari-
ables. Random effects were included in the model to
account for a lack of independence in each sampling due
to multiple calves housed within the same pen and
repeated measures on individual calves. Pairwise com-
parisons were performed to determine statistically sig-
nificant differences.
Summary measures of cortisol including peak
plasma concentration (Cmax), time to peak concentra-
tion (Tmax) and area under the time-effect curve
(AUEC) were determined as previously described [47]
using the linear trapezoidal rule and WinNonlin soft-
ware (Pharsight Corporation, Cary, NC). Analysis of
variance (ANOVA) was employed to evaluate differ-
ences in single measurement, normally distributed
data (ADG, Cmax, and AUEC). The Kruskal-Wallis
Test was used to analyze non-parametric data (Tmax).
In order to determine the relationship between
plasma meloxicam concentrations, SP and serum cor-
tisol concentrations at the corresponding time points
after dehorning, post hoc linear regression curves were
constructed using the log-transformed percentage
change from baseline. Statistical significance was
designated a priori at p<0.05.Competing interests
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